Tags

Type your tag names separated by a space and hit enter

Hypercalcemia of Malignancy.
Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.EM

Abstract

Hypercalcemia of malignancy (HCM) is considered an oncologic emergency associated with significant symptom burden and increased comorbid conditions and mortality. Underlying pathologic processes most often stimulate osteoclast-mediated bone resorption. Although long-term control of HCM depends on effective management of the underlying cancer, temporizing management strategies for acute and/or symptomatic HCM include hydration and antiresorptive bone-modifying agents. Although most patients respond well to the antiresorptive therapies available, further investigation into other agents for those who are refractory to both bisphosphonates and denosumab is needed.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Hu MI
Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA. Electronic address: mhu@mdanderson.org.

MeSH

Bone Density Conservation AgentsDenosumabDiphosphonatesHumansHypercalcemiaNeoplasmsParaneoplastic Syndromes

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34774243

Citation

Hu, Mimi I.. "Hypercalcemia of Malignancy." Endocrinology and Metabolism Clinics of North America, vol. 50, no. 4, 2021, pp. 721-728.
Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021;50(4):721-728.
Hu, M. I. (2021). Hypercalcemia of Malignancy. Endocrinology and Metabolism Clinics of North America, 50(4), 721-728. https://doi.org/10.1016/j.ecl.2021.07.003
Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021;50(4):721-728. PubMed PMID: 34774243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypercalcemia of Malignancy. A1 - Hu,Mimi I, PY - 2021/11/14/entrez PY - 2021/11/15/pubmed PY - 2022/4/1/medline KW - Antiresorptive therapy KW - Cancer KW - Etiology KW - Evaluation KW - Hypercalcemia KW - Refractory SP - 721 EP - 728 JF - Endocrinology and metabolism clinics of North America JO - Endocrinol Metab Clin North Am VL - 50 IS - 4 N2 - Hypercalcemia of malignancy (HCM) is considered an oncologic emergency associated with significant symptom burden and increased comorbid conditions and mortality. Underlying pathologic processes most often stimulate osteoclast-mediated bone resorption. Although long-term control of HCM depends on effective management of the underlying cancer, temporizing management strategies for acute and/or symptomatic HCM include hydration and antiresorptive bone-modifying agents. Although most patients respond well to the antiresorptive therapies available, further investigation into other agents for those who are refractory to both bisphosphonates and denosumab is needed. SN - 1558-4410 UR - https://www.unboundmedicine.com/medline/citation/34774243/Hypercalcemia_of_Malignancy_ DB - PRIME DP - Unbound Medicine ER -